2018 American Society of Hematology Annual Meeting*

Hematology 2018 Conference Image
Download All
December 1-4, 2018; San Diego, California
Review slidesets and analyses of key data from the 2018 Hematology meeting.


Capsule Slidesets

2-year PFS was significantly increased with ibrutinib vs BR but was not further improved by addition of rituximab.

Released: December 6, 2018

Ongoing combination therapy achieved improved responses, including in older patients and across all high-risk groups, with 96% and 69% of patients achieving CR/CRi and BM MRD negativity, respectively, at 18 months.

Released: December 12, 2018

In a combined analysis of KEYNOTE-013 and KEYNOTE-170, relapsed/refractory PMBCL patients who received pembrolizumab showed durable responses, with more than one half of patients alive at 1 year.

Released: December 6, 2018

Combined BRAF and MEK inhibition was well tolerated and achieved a high rate of durable responses in this heavily pretreated patient population.

Released: December 10, 2018

The rituximab biosimilar candidate PF-05280586 showed therapeutic equivalence and a similar safety profile vs reference rituximab-EU in previously untreated patients with CD20-positive low tumor burden follicular lymphoma.

Released: December 6, 2018

Combination of rituximab with lenalidomide showed significantly improved disease control vs rituximab alone in this blinded study.

Released: December 7, 2018

Addition of ibrutinib to obinutuzumab reduced risk of progression or death compared with chlorambucil plus obinutuzumab, including in patients with bulky disease and high-risk cytogenetics.

Released: December 17, 2018

BTK inhibitor demonstrates durable efficacy and tolerability in patients with previously untreated CLL in this early-phase study.

Released: December 18, 2018

Efficacy with R-CHOP x 4 → R x 2 was noninferior to R-CHOP x 6 with a decrease in the number of nonhematologic adverse events by approximately one third.

Released: December 3, 2018

EFS, PFS, and OS were prolonged among patients younger than 60 years who were treated with ibrutinib + R-CHOP vs placebo + R-CHOP.

Released: December 14, 2018

Frontline BV + CHP achieved superior PFS and OS vs standard CHOP with a manageable safety profile, leading to the recent FDA approval in this setting.

Released: December 11, 2018

This primary analysis demonstrated a statistically significant improvement in both PFS and OS with first-line ibrutinib plus rituximab vs FCR in patients younger than 70 years of age.

Released: December 7, 2018

PET-positive patients with limited-stage DLBCL who received PET-directed radiotherapy and ibritumomab tiuxetan after 3 cycles R-CHOP had similar 5-year PFS and OS rates as PET-negative patients who received an additional cycle of R-CHOP.

Released: December 19, 2019

In a 2-year follow-up analysis of ZUMA-1, patients with refractory large B-cell lymphoma who received axicabtagene ciloleucel showed durable responses, including patients with high-risk disease.

Released: March 14, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings